There's a new beacon of hope in HIV prevention. Recent results from a phase 3 trial reveal that a twice-yearly injection of the drug to treat AIDS offers 100% efficacy in preventing new infections.
In a landmark trial involving 5,000 young women and adolescent girls in South Africa and Uganda, not a single HIV infection was reported among those who received two shots of lenacapavir, from drugmaker Gilead.
